20Jan 2017

The Effect of Interferon/Ribavirin Therapy on the Levels of Angiopoetin-2 andTIE-2 in Chronic Hepatitis C Patients.

  • Department of Tropical Medicine and Hepatology, Cairo University, Cairo, Egypt.
  • Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Department of Endemic and Infectious diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Department of Internal Medicine, Taibah University, Medina, Saudi Arabia.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Aim: to identify the effect of hepatitis C virus treatment by pegylated interferon and ribavirin on the level of angiogenic factor (Angiopoetin -2 and its receptor Tie-2) and detection of their levels as a predictor of response to treatment. Methods: one hundredand sixteen patients with chronic hepatitis C, who were candidate for interferon and ribavirin combination therapy according to the Egyptian Ministry of Health Program, enrolled in this study where the levels ofAngiopoetin -2 and its receptor Tie-2were determinedbefore and after the combination therapy. Results:There was a significant decline of serum Ang-2 after the end of treatment, week 48 (330.8 ± 73.0) compared to the baseline values (544.7 ± 64.1) in all patients (P<0.0 1),while There was a significant increase of serum sTie-2after the end of treatment, week 48 (31.2 ± 1.04) compared to the baseline values (17.7 ± 2.1) in all patients (P<0.0 1). However there was no difference between responders (212.5 ± 87.1) and non-responders (228.3 ± 22.9) at week 48 regarding serum Ang-2, and also there was no difference between responders (13.4 ± 2.4) and non-responders (14.22 ± 2.39) at week 48 regarding serum Tie-2(P<0.0 1). Conclusion: Angiopoetin -2 and its receptor Tie-2 may not be a useful predictors for treatment responses to pegylated interferon and ribavirin.


  • Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107–15.
  • El-Zanaty F and Way A. Egypt Demographic and Health Survey 2008. Egyptian:Ministry of Health (El-Zanaty and Associates and Macro International, Cairo), 2009; pp 431.
  • Fattovich G1, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50.
  • Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008; 48:148–162.
  • Stewart S, Day C. The management of alcoholic liver disease Hepatol 2003; 38 (Supp l. 1): S2–13.
  • Coulon, F. Heindryckx, A. Geerts, C. Van Steenkiste, I. Colle, H. Van Vlierberghe. Angiogenesis in chronic liver disease and its complications. Liver Int, 31 (2011), pp. 146–1627.
  • Yamamoto T, Hirohashi K, Kaneda K, et al. Relationship of the microvascular type to the tumor size, arterialization and dedifferentiation of humanhepatocellular carcinoma. Jpn J Cancer Res 2001; 92: 1207–13.
  • Yoshiji H, Kuriyama S, Fukui H. Blockade of reninangiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007; 22(Suppl.1): S93–5.
  • Zeuzem S,Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23(Suppl 1):23-28.
  • Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatol. 2008; 47:43-50.
  • Semela D and J.-F. Dufour. “Angiogenesis and hepatocellular carcinoma,” Journal of Hepatology. 2004; vol. 41, no. 5, pp. 864–880.
  • Visconti RP, Richardson C, Sato T. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad SciUSA. 2002; 99:8219-8224.
  • Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9:653-660.
  • Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.Gastroenterol. 2004; 126:1302-1311.
  • World Health Organization: Hepatitis C – global prevalence. Weekly Epidemiological Record, (2009); 75(3): 18–9.
  • Mohamed A. Abdel Mohsen, Neveen A. Hussein, Abeer A. Ghazal, et al. Angiogenic output in viral hepatitis, C and B, and HCV-associated hepatocellular carcinoma, Alexandria Journal of Medicine. 2014; vol 50, 235–240.
  • Salcedo X, Medina J, Sanz-Cameno P, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology. 2005; 42: 696-701.
  • Abdel-Mohsen M1, Deng X2, Danesh A2, Liegler T3, Jacobs ES2, Rauch A4, Ledergerber B5, Norris PJ6, Günthard HF5, Wong JK7, Pillai SK8. Role of microRNA modulation in the interferon-?/ribavirin suppression of HIV-1 in vivo.PLoS One. 2014 Oct 2;9(10.
  • Wada; Nagano; Yamamoto; et al. Combination therapy of interferon-? and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins, Oncol Rep. 2007; Oct;18(4):801-9.
  • White CW, Sondheimer H, Crouch E, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med.1989; 320:1197-1200.
  • Marler JJ, Rubin JB, Trede NS, Connors S, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alpha 2b: Report of 2 cases; pediatrics 2002, 109: E 37.
  • Palmieri G, Montella L, Martignetti A et al., Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report. Oncol Rep.2000; 7:145-149.
  • Helaly GF, Abou Shamaa LA. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC, Egypt J Immunol. 2006; 13(1):27-38.
  • Ángel Hernández-Bartolomé, Rosario López-Rodríguez, Yolanda Rodríguez-Muñoz, et al. Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link, PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6
  • Beata Kasztelan-Szczerbinska, 1 ,* Agata Surdacka, 2 Maria Slomka, 1 Jacek Rolinski, 2 Krzysztof Celinski, 1 Halina Cichoz-Lach, 1 Agnieszka Madro, 1 and Mariusz Szczerbinski 1. Angiogenesis-Related Biomarkers in Patients with Alcoholic Liver Disease: Their Association with Liver Disease Complications and Outcome. Mediators Inflamm. 2014; 2014: 673032. Published online 2014 May 18. doi:  1155/2014/673032.

[Gamal Esmat, Khalil A. Khalil, Mohamed Abdou, Fadia Mustafa, Ayman Salem, Mahmoud Shedid, and Mohamed Mosaad. (2017); The Effect of Interferon/Ribavirin Therapy on the Levels of Angiopoetin-2 andTIE-2 in Chronic Hepatitis C Patients. Int. J. of Adv. Res. 5 (1). 734-740] (ISSN 2320-5407). www.journalijar.com


Mohamed Mosaad
4- Department of Endemic and Infectious diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt ; 5- Department of Internal Medicine, Taibah University, Medina, Saudi Arabia

DOI:


Article DOI: 10.21474/IJAR01/2808       DOI URL: http://dx.doi.org/10.21474/IJAR01/2808


Share this article